Novo Nordisk A/S (NVO)
| Market Cap | 213.92B |
| Revenue (ttm) | 49.11B |
| Net Income (ttm) | 17.49B |
| Shares Out | 4.44B |
| EPS (ttm) | 3.93 |
| PE Ratio | 12.41 |
| Forward PE | 12.48 |
| Dividend | $1.18 (2.42%) |
| Ex-Dividend Date | Mar 31, 2025 |
| Volume | 40,780,515 |
| Open | 48.47 |
| Previous Close | 45.38 |
| Day's Range | 47.92 - 49.10 |
| 52-Week Range | 45.05 - 139.74 |
| Beta | 0.27 |
| Analysts | Buy |
| Price Target | 112.00 (+129.7%) |
| Earnings Date | Aug 6, 2025 |
About NVO
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrin... [Read more]
Financial Performance
In 2024, Novo Nordisk's revenue was 290.40 billion, an increase of 25.03% compared to the previous year's 232.26 billion. Earnings were 100.99 billion, an increase of 20.68%.
Financial numbers in DKK Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for NVO stock is "Buy." The 12-month stock price target is $112.0, which is an increase of 129.70% from the latest price.
News
Baron Capital's Top Health Care Stock Picks And Misses From Q2 2025
We added key positions in Masimo, Exact Sciences, Eli Lilly, Penumbra, and Edwards Lifesciences, each with strong growth drivers and market leadership. Our investment in Masimo is supported by divesti...
Final Trade: AAPL, NOVO, RL
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of September 30, 2025 in Novo Lawsuit – NVO
NEW YORK, Aug. 07, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Novo Nordisk A/S (NYSE: NVO).
Drugmakers racing to launch the first weight-loss pill
Weight-loss drugs are expected to pull in more than $150 billion in industry-wide revenue by the early 2030s, thanks to the ever-growing popularity of Eli Lilly's Zepbound and Novo Nordisk's Wegovy.
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
Bagsværd, Denmark, 7 August 2025 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated person...
VIEW Lilly's obesity pill lags Novo's Wegovy injection in key trial
Eli Lilly said on Thursday that its experimental GLP-1 pill helped patients lose 12.4% of their body weight after 72 weeks in a late-stage study, less than previous trial results for Novo Nordisk's in...
Novo Nordisk: The Market Has Lost Its Mind
Novo Nordisk's shares have dropped significantly despite appealing Q2 results, creating an attractive entry point for long-term investors. The company continues to deliver double-digit revenue and pro...
Novo Nordisk shares jump as Eli Lilly's weight-loss pill data disappoints
Shares in Novo Nordisk rose 13.6% on Thursday after trial data from Eli Lilly's experimental weight-loss pill fell short of expectations, boosting investor confidence in the Danish drugmaker's market-...
Novo Nordisk: More Pain On The Horizon
Novo Nordisk faces slowing revenue growth, weak Q2 2025 results, and a more conservative outlook, signaling challenges ahead. Competition from Eli Lilly is intensifying, forcing Novo to increase marke...
Novo Nordisk A/S (NVO) Q2 2025 Earnings Call Transcript
Novo Nordisk A/S (NVO) Q2 2025 Earnings Conference Call August 6, 2025 7:00 AM ET Company Participants David S. Moore - Executive VP of US Operations & Member of Management Board Jacob Martin Wiborg R...
Novo Nordisk's Wegovy Weight-Loss Drug Sales Surge Despite Copycat Issues
Second-quarter sales of the blockbuster drug soared 67% on year, despite millions of U.S. patients using generic unbranded versions of the drug.
Wegovy maker Novo Nordisk's sales hike in second quarter
Wegovy maker Novo Nordisk's sales hike in second quarter
Wegovy maker Novo Nordisk sales rise 18% in second quarter
Wegovy-maker Novo Nordisk reported second-quarter sales up 18% on Wednesday, below initial analyst expectations, after a major profit warning and new CEO announcement last week wiped some $95 billion ...
Novo Nordisk's sales increased by 16% in Danish kroner and by 18% at constant exchange rates to DKK 154.9 billion in the first six months of 2025
Bagsværd, Denmark, 6 August 2025 - Financial report for the period 1 January 2025 to 30 June 2025
Novo Nordisk's weight loss challenge in five charts
Danish drugmaker Novo Nordisk is facing a major challenge to its blockbuster weight-loss drug Wegovy.
Novo Nordisk's Earnings Come After a Dramatic Guidance Cut. What to Look for Now.
The drugmaker is slated to report its second-quarter financial results early Wednesday.
Novo Nordisk expands legal action to protect patients from non-FDA approved weight-loss drugs
CNBC's Brandon Gomez and Angelica Peebles join 'Power Lunch' to break down the biggest headlines in the pharmaceutical space.
Novo Nordisk expands lawsuits against weight-loss drug compounders
Danish drugmaker Novo Nordisk said on Tuesday it has filed 14 new lawsuits in the United States against the sale of unapproved versions of semaglutide, the main ingredient in its popular weight-loss a...
Weighing HIMS GLP-1 Trends, NVO Partnership & Other Businesses
Michael Cherny sees opportunity for Hims & Hers (HIMS), as long as it can overcome headwinds facing its non-weight loss businesses. He argues the stock hasn't traded on fundamentals and weighs heavily...
Novo Nordisk Stock Catches a Downgrade. The Eli Lilly Threat Is Just One Reason.
Novo Nordisk stock was downgraded to Neutral from Buy by UBS analysts, who cited the threat posed by its U.S. rival.
Novo Nordisk stock downgraded as Trump teases 250% pharma tariffs
Novo Nordisk (NYSE: NVO) is inching down on market open today after President Donald Trump said pharma tariffs could hit 250% as he continues to push for drug manufacturing to return to the US.
GLP-1 War: A Look At The Epic Pipeline Battle Between Novo Nordisk And Eli Lilly
Novo Nordisk's share price collapse is an overreaction; the market underestimates its robust pipeline and continued double-digit growth potential. The GLP-1 obesity drug market is massive and supports...
Novo Nordisk is no longer a buy at UBS, which says compounding is here to stay
Novo Nordisk, the Danish maker of the wildly popular Ozempic and Wegovy drugs used for weight loss, was downgraded due to competition from compounding as well as arch rival Eli Lilly, a brokerage said...
NOVO NORDISK A/S (NYSE: NVO) INVESTOR ALERT – Investors With Large Losses in Novo Nordisk A/S Should Contact Bernstein Liebhard LLP To Discuss Their Rights
NEW YORK, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquir...
Watch These Novo Nordisk Stock Price Levels After Last Week's 33% Drop
Novo Nordisk's (NVO) U.S.-listed shares were up about 2% in recent trading after shedding about a third of their value last week, when the company cut its full-year outlook and named a new CEO, leadin...